Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Coates

Showing results (231-240 of 240) with videos related to

Pageof 24
Sort By:
You have reached the last page of results.This site can display upto 240 results.
JCI Insight|April 8, 2024
Phase 1 trial evaluating safety and pharmacokinetics of HIV-1 broadly neutralizing mAbs 10E8VLS and VRC07-523LSSeemal F Awan, Amarendra Pegu, Larisa Strom, et al.
Nature Medicine|March 13, 2026
A structure-based mRNA vaccine for Nipah virus in healthy adults: a phase 1 trialAurélie Ploquin, Rosemarie D Mason, LaSonji A Holman, et al.
Science (New York, N.Y.)|December 14, 2023
HIV vaccines induce CD8<sup>+</sup> T cells with low antigen receptor sensitivityStephen A Migueles, Danielle M Nettere, Noah V Gavil, et al.
Eclinicalmedicine|July 5, 2022
Safety and immunogenicity of an HIV-1 prefusion-stabilized envelope trimer (Trimer 4571) vaccine in healthy adults: A first-in-human open-label, randomized, dose-escalation, phase 1 clinical trialKatherine V Houser, Martin R Gaudinski, Myra Happe, et al.
Nature Medicine|February 4, 2022
Safety and immunogenicity of a ferritin nanoparticle H2 influenza vaccine in healthy adults: a phase 1 trialKatherine V Houser, Grace L Chen, Cristina Carter, et al.
Nature Medicine|April 12, 2022
Safety and tolerability of AAV8 delivery of a broadly neutralizing antibody in adults living with HIV: a phase 1, dose-escalation trialJoseph P Casazza, Evan M Cale, Sandeep Narpala, et al.
Science Translational Medicine|April 19, 2023
An influenza hemagglutinin stem nanoparticle vaccine induces cross-group 1 neutralizing antibodies in healthy adultsAlicia T Widge, Amelia R Hofstetter, Katherine V Houser, et al.
The New England Journal of Medicine|August 3, 2022
Low-Dose Subcutaneous or Intravenous Monoclonal Antibody to Prevent MalariaRichard L Wu, Azza H Idris, Nina M Berkowitz, et al.
The Lancet. Infectious Diseases|August 6, 2023
Safety, tolerability, and immunogenicity of the Ebola Sudan chimpanzee adenovirus vector vaccine (cAd3-EBO S) in healthy Ugandan adults: a phase 1, open-label, dose-escalation clinical trialBetty Mwesigwa, Katherine V Houser, Amelia R Hofstetter, et al.
Lancet (London, England)|January 28, 2023
Safety, tolerability, and immunogenicity of the chimpanzee adenovirus type 3-vectored Marburg virus (cAd3-Marburg) vaccine in healthy adults in the USA: a first-in-human, phase 1, open-label, dose-escalation trialMelinda J Hamer, Katherine V Houser, Amelia R Hofstetter, et al.
Pageof 24

Showing results (231-240 of 240) with videos related to

Sort By:
Pageof 24
You have reached the last page of results.This site can display upto 240 results.
JCI Insight|April 8, 2024
Phase 1 trial evaluating safety and pharmacokinetics of HIV-1 broadly neutralizing mAbs 10E8VLS and VRC07-523LSSeemal F Awan, Amarendra Pegu, Larisa Strom, et al.
Nature Medicine|March 13, 2026
A structure-based mRNA vaccine for Nipah virus in healthy adults: a phase 1 trialAurélie Ploquin, Rosemarie D Mason, LaSonji A Holman, et al.
Science (New York, N.Y.)|December 14, 2023
HIV vaccines induce CD8<sup>+</sup> T cells with low antigen receptor sensitivityStephen A Migueles, Danielle M Nettere, Noah V Gavil, et al.
Eclinicalmedicine|July 5, 2022
Safety and immunogenicity of an HIV-1 prefusion-stabilized envelope trimer (Trimer 4571) vaccine in healthy adults: A first-in-human open-label, randomized, dose-escalation, phase 1 clinical trialKatherine V Houser, Martin R Gaudinski, Myra Happe, et al.
Nature Medicine|February 4, 2022
Safety and immunogenicity of a ferritin nanoparticle H2 influenza vaccine in healthy adults: a phase 1 trialKatherine V Houser, Grace L Chen, Cristina Carter, et al.
Nature Medicine|April 12, 2022
Safety and tolerability of AAV8 delivery of a broadly neutralizing antibody in adults living with HIV: a phase 1, dose-escalation trialJoseph P Casazza, Evan M Cale, Sandeep Narpala, et al.
Science Translational Medicine|April 19, 2023
An influenza hemagglutinin stem nanoparticle vaccine induces cross-group 1 neutralizing antibodies in healthy adultsAlicia T Widge, Amelia R Hofstetter, Katherine V Houser, et al.
The New England Journal of Medicine|August 3, 2022
Low-Dose Subcutaneous or Intravenous Monoclonal Antibody to Prevent MalariaRichard L Wu, Azza H Idris, Nina M Berkowitz, et al.
The Lancet. Infectious Diseases|August 6, 2023
Safety, tolerability, and immunogenicity of the Ebola Sudan chimpanzee adenovirus vector vaccine (cAd3-EBO S) in healthy Ugandan adults: a phase 1, open-label, dose-escalation clinical trialBetty Mwesigwa, Katherine V Houser, Amelia R Hofstetter, et al.
Lancet (London, England)|January 28, 2023
Safety, tolerability, and immunogenicity of the chimpanzee adenovirus type 3-vectored Marburg virus (cAd3-Marburg) vaccine in healthy adults in the USA: a first-in-human, phase 1, open-label, dose-escalation trialMelinda J Hamer, Katherine V Houser, Amelia R Hofstetter, et al.
Pageof 24